JP2010503688A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010503688A5 JP2010503688A5 JP2009528337A JP2009528337A JP2010503688A5 JP 2010503688 A5 JP2010503688 A5 JP 2010503688A5 JP 2009528337 A JP2009528337 A JP 2009528337A JP 2009528337 A JP2009528337 A JP 2009528337A JP 2010503688 A5 JP2010503688 A5 JP 2010503688A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- aryl
- compound according
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84522706P | 2006-09-15 | 2006-09-15 | |
| US60/845,227 | 2006-09-15 | ||
| PCT/US2007/020201 WO2008033567A1 (en) | 2006-09-15 | 2007-09-14 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010503688A JP2010503688A (ja) | 2010-02-04 |
| JP2010503688A5 true JP2010503688A5 (enExample) | 2010-10-28 |
| JP5567339B2 JP5567339B2 (ja) | 2014-08-06 |
Family
ID=38983295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009528337A Active JP5567339B2 (ja) | 2006-09-15 | 2007-09-14 | Ｎ−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8648096B2 (enExample) |
| EP (1) | EP2076260B1 (enExample) |
| JP (1) | JP5567339B2 (enExample) |
| KR (1) | KR20090050107A (enExample) |
| CN (2) | CN103382197A (enExample) |
| AR (1) | AR062875A1 (enExample) |
| AT (1) | ATE502634T1 (enExample) |
| CA (1) | CA2663376C (enExample) |
| CL (1) | CL2007002670A1 (enExample) |
| CO (1) | CO6180446A2 (enExample) |
| CR (1) | CR10696A (enExample) |
| CY (1) | CY1112558T1 (enExample) |
| DE (1) | DE602007013436D1 (enExample) |
| DK (1) | DK2076260T3 (enExample) |
| ES (1) | ES2361584T3 (enExample) |
| HR (1) | HRP20110261T1 (enExample) |
| IL (1) | IL197566A0 (enExample) |
| MX (1) | MX2009002666A (enExample) |
| NI (1) | NI200900031A (enExample) |
| NZ (1) | NZ575689A (enExample) |
| PE (1) | PE20080832A1 (enExample) |
| PL (1) | PL2076260T3 (enExample) |
| PT (1) | PT2076260E (enExample) |
| RS (1) | RS51725B (enExample) |
| RU (1) | RU2009114159A (enExample) |
| SI (1) | SI2076260T1 (enExample) |
| TW (1) | TW200819435A (enExample) |
| UA (1) | UA95975C2 (enExample) |
| WO (1) | WO2008033567A1 (enExample) |
| ZA (1) | ZA200901852B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2437592T3 (es) * | 2004-09-03 | 2014-01-13 | Celgene Corporation | Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas |
| RS52704B (sr) | 2005-06-30 | 2013-08-30 | Celgene Corporation | Postupci za dobijanje 4-amino-2-(2,6-dioksopiperidin-3-il) izoindolin-1,3-dionskih jedinjenja |
| RU2009114159A (ru) * | 2006-09-15 | 2010-10-20 | Селджин Корпорейшн (Us) | N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения |
| US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
| MX361467B (es) * | 2008-10-29 | 2018-12-06 | Celgene Corp | Compuestos de isoindolina para uso en el tratamiento de cancer. |
| BRPI0923164A2 (pt) | 2008-12-19 | 2016-01-26 | Graceway Pharmaceuticals Llc | formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica. |
| GEP20156418B (en) | 2009-07-13 | 2016-01-11 | Medicis Pharmaceutical Corp | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| PL2536706T3 (pl) | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| US11295846B2 (en) | 2011-12-21 | 2022-04-05 | Deka Products Limited Partnership | System, method, and apparatus for infusing fluid |
| US9540340B2 (en) | 2013-01-14 | 2017-01-10 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US9365527B2 (en) | 2013-03-14 | 2016-06-14 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| HRP20202008T1 (hr) | 2013-03-14 | 2021-02-19 | Epizyme, Inc. | Inhibitori arginin-metiltransferaze i njihove uporabe |
| AU2014260433A1 (en) | 2013-03-14 | 2015-09-10 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
| WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9290475B2 (en) | 2013-03-14 | 2016-03-22 | Deuterx, Llc | 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| JP2016518336A (ja) | 2013-03-14 | 2016-06-23 | エピザイム，インコーポレイティド | Ｐｒｍｔ１阻害剤としてのピラゾール誘導体およびその使用 |
| US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| AU2014254056B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| CA2957225A1 (en) | 2014-08-07 | 2016-02-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| WO2017040376A1 (en) * | 2015-08-31 | 2017-03-09 | The University Of Toledo | Potent phthalate inhibitors of aspartate n-acetyltransferase and selective aspartate pathway inhibitors |
| TWI728017B (zh) | 2015-12-15 | 2021-05-21 | 瑞典商阿斯特捷利康公司 | 異吲哚化合物、包含其之醫藥組成物及其用途 |
| AU2017246453A1 (en) * | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| JP2019537585A (ja) | 2016-10-28 | 2019-12-26 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｅｚｈ２媒介性がんを治療するための組成物および方法 |
| CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| JP2020524660A (ja) | 2017-06-14 | 2020-08-20 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| CN112312904B (zh) | 2018-04-16 | 2025-01-07 | C4医药公司 | 螺环化合物 |
| SG11202009237XA (en) * | 2018-04-23 | 2020-10-29 | Celgene Corp | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| JP2021527666A (ja) | 2018-06-21 | 2021-10-14 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法 |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| AR119715A1 (es) * | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| CN114423463B (zh) | 2019-05-06 | 2025-09-26 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| MX2022004688A (es) * | 2019-10-21 | 2022-05-10 | Celgene Corp | Métodos para tratar un cáncer hematológico y uso de biomarcadores compañeros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-mor folinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona. |
| CA3154510A1 (en) | 2019-10-21 | 2021-04-29 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| CN114929686A (zh) * | 2019-10-21 | 2022-08-19 | 新基公司 | 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮及其盐的固体形式，以及含有其的组合物及它们的用途 |
| CN110746400B (zh) * | 2019-11-07 | 2021-12-17 | 郑州大学 | 一种靶向雄激素受体的荧光探针及其制备方法 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| EP4446324A1 (en) * | 2021-12-08 | 2024-10-16 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Ligand compounds for e3 ubiquitin ligase, protein degraders developed on basis of ligand compounds, and uses thereof |
| EP4536656A1 (en) | 2022-06-06 | 2025-04-16 | C4 Therapeutics, Inc. | Bicyclic-substituted glutarimide cereblon binders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| ES2243052T3 (es) * | 1998-03-16 | 2005-11-16 | Celgene Corporation | Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias. |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CA2508171C (en) * | 2002-12-13 | 2012-08-28 | Cytopia Pty Ltd | Nicotinamide-based kinase inhibitors |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| RS52704B (sr) * | 2005-06-30 | 2013-08-30 | Celgene Corporation | Postupci za dobijanje 4-amino-2-(2,6-dioksopiperidin-3-il) izoindolin-1,3-dionskih jedinjenja |
| RU2009114159A (ru) * | 2006-09-15 | 2010-10-20 | Селджин Корпорейшн (Us) | N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения |
-
2007
- 2007-09-14 RU RU2009114159/15A patent/RU2009114159A/ru not_active Application Discontinuation
- 2007-09-14 DE DE602007013436T patent/DE602007013436D1/de active Active
- 2007-09-14 PT PT07838415T patent/PT2076260E/pt unknown
- 2007-09-14 US US11/901,291 patent/US8648096B2/en active Active
- 2007-09-14 CA CA2663376A patent/CA2663376C/en active Active
- 2007-09-14 SI SI200730569T patent/SI2076260T1/sl unknown
- 2007-09-14 KR KR1020097006986A patent/KR20090050107A/ko not_active Withdrawn
- 2007-09-14 UA UAA200903664A patent/UA95975C2/ru unknown
- 2007-09-14 TW TW096134612A patent/TW200819435A/zh unknown
- 2007-09-14 ZA ZA200901852A patent/ZA200901852B/xx unknown
- 2007-09-14 NZ NZ575689A patent/NZ575689A/en not_active IP Right Cessation
- 2007-09-14 JP JP2009528337A patent/JP5567339B2/ja active Active
- 2007-09-14 ES ES07838415T patent/ES2361584T3/es active Active
- 2007-09-14 RS RS20110258A patent/RS51725B/sr unknown
- 2007-09-14 HR HR20110261T patent/HRP20110261T1/hr unknown
- 2007-09-14 CL CL200702670A patent/CL2007002670A1/es unknown
- 2007-09-14 WO PCT/US2007/020201 patent/WO2008033567A1/en not_active Ceased
- 2007-09-14 PL PL07838415T patent/PL2076260T3/pl unknown
- 2007-09-14 CN CN2013102182141A patent/CN103382197A/zh active Pending
- 2007-09-14 DK DK07838415.3T patent/DK2076260T3/da active
- 2007-09-14 AT AT07838415T patent/ATE502634T1/de active
- 2007-09-14 CN CNA2007800424312A patent/CN101534820A/zh active Pending
- 2007-09-14 EP EP07838415A patent/EP2076260B1/en active Active
- 2007-09-14 MX MX2009002666A patent/MX2009002666A/es active IP Right Grant
- 2007-09-17 AR ARP070104112A patent/AR062875A1/es unknown
- 2007-09-17 PE PE2007001253A patent/PE20080832A1/es not_active Application Discontinuation
-
2009
- 2009-03-12 IL IL197566A patent/IL197566A0/en unknown
- 2009-03-13 NI NI200900031A patent/NI200900031A/es unknown
- 2009-03-30 CR CR10696A patent/CR10696A/es not_active Application Discontinuation
- 2009-04-03 CO CO09034806A patent/CO6180446A2/es not_active Application Discontinuation
-
2011
- 2011-05-20 CY CY20111100500T patent/CY1112558T1/el unknown
-
2013
- 2013-12-30 US US14/144,292 patent/US20140113935A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010503688A5 (enExample) | ||
| RU2009114159A (ru) | N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения | |
| RU2009111273A (ru) | 5-замещенные изоиндолиновые соединения | |
| JP2013542218A5 (enExample) | ||
| ES2752039T3 (es) | Agente terapéutico para la dislipidemia | |
| ME01421B (me) | 5-supstituisani derivati kinazolinona kao protivtumorska sredstva | |
| JP2014511891A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2010540525A5 (enExample) | ||
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| JP2012502037A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| JP2018135343A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| AR055669A1 (es) | Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales. | |
| JP2008539268A5 (enExample) | ||
| JP2006524660A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| RU2016134751A (ru) | Соединения | |
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| JP2010523476A5 (enExample) | ||
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| JP2013545823A5 (enExample) |